Comparative Pharmacology
Head-to-head clinical analysis: INDIUM IN 111 OXYQUINOLINE versus IODOHIPPURATE SODIUM I 131.
Peer-Reviewed Evidence
Head-to-head clinical analysis: INDIUM IN 111 OXYQUINOLINE versus IODOHIPPURATE SODIUM I 131.
INDIUM IN 111 OXYQUINOLINE vs IODOHIPPURATE SODIUM I 131
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Indium In 111 oxyquinoline is a radiolabeled compound that chelates indium-111 with oxyquinoline. The lipophilic complex penetrates cell membranes and binds to intracellular components, primarily in leukocytes (neutrophils). After intravenous injection, the radiolabeled cells accumulate at sites of inflammation or infection, allowing gamma camera imaging to detect focal areas of abnormal leukocyte localization.
Iodohippurate sodium I 131 is a radioactive diagnostic agent that is actively transported by the renal tubules, allowing imaging of renal morphology and function. The iodine-131 emits gamma radiation, enabling scintigraphic evaluation of renal blood flow, tubular secretion, and excretion.
1-2 mCi (37-74 MBq) labeled autologous leukocytes, administered intravenously over 1-2 minutes.
Adult: 5-30 microcuries (0.185-1.11 MBq) intravenously for renal function studies.
None Documented
None Documented
Terminal elimination half-life is approximately 4-6 hours for the free indium ion, but biological half-life for labeled cells can be 1-2 days depending on cell type.
Terminal elimination half-life is approximately 60 minutes in patients with normal renal function. In renal impairment, half-life may be prolonged up to several hours, correlating with reduced clearance.
Renal excretion approximately 70-80% within 24 hours; fecal excretion less than 5%.
Primarily renal; >90% of administered dose excreted unchanged in urine within 24 hours via glomerular filtration and tubular secretion. Fecal excretion <2%.
Category C
Category C
Radiopharmaceutical
Radiopharmaceutical